Wall St. Cheat Sheet » Financial Business »

4 Heathcare Stock Stories Attracting Investor Attention

January 25, 2013

Page 1 of 4

Biodel (NASDAQ:BIOD) Current price $2.70

On Thursday, the firm reported positive top-line results from a Phase 1 clinical trial of two ultra-rapid-acting insulin analog-based formulations, BIOD-238 and BIOD-250, conducted to study the pharmacokinetic and injection site toleration profiles relative to Humalog, which is a quickly-acting insulin analog. BIOD-238 and BIOD-250 are combinations of Biodel’s proprietary excipients with the marketed formulation of Humalog.

biod

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

Page 1 of 4

view all

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com